Health ProductsPublic Communication

Archived – New Warnings about Parkinson's Drug PERMAX® and Reports of Heart Valve Problems – Shire BioChem Inc. – For the Public

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Drugs
Issue: Important Safety Information
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Shire Biochem Inc..
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

[Text of letter begins]

PUBLIC ADVISORY
Health Canada Endorsed Important Safety Information on PERMAX® (pergolide mesylate)

Subject: Shire Biochem Inc. Issues New Warnings about Parkinson's Drug PERMAX® and Reports of Heart Valve Problems

MONTREAL, October 2004 - Further to discussions with Health Canada, Shire BioChem Inc. has recently informed healthcare professionals of new safety information concerning PERMAX® (pergolide mesylate) a medication used primarily in the treatment of Parkinson's disease. In two recent studies, the echocardiograms of a significant number of patients treated with PERMAX® showed evidence of cardiac valvulopathy, a condition involving inflammation or stiffening of the heart valves. Although cardiac valvular disease has been reported previously, albeit rarely, the recent reports suggest that the condition may occur more frequently than was previously thought. It is noted that because there are a number of limitations with the studies, the actual rate of cardiac valvular disease with PERMAX® cannot be determined at this time. However, given the potentially serious nature of these events and the known similar effects of other ergot-derived drugs, a warning is being issued to physicians and patients, and the prescribing information for PERMAX® is being modified accordingly.

Shire BioChem Inc., in discussion with Health Canada, recently issued a "Dear Health Care Professional" letter asking prescribing physicians to re-assess the risks and benefits of PERMAX® treatment for their patients as compared to the risks and benefits of non-ergot based treatment, and to monitor the patient on a periodic basis for valvular disease. Physicians have also been advised to inform patient/caregivers of the risk of cardiac valvular disease and other serous fibrotic reactions. It is recommended that patients starting PERMAX® should undergo a cardiovascular evaluation, including an echocardiogram.

Patients currently taking PERMAX®, or their caregivers, should talk to their doctor about whether an echocardiogram is required in their individual case.

The revised prescribing information will recommend cardiovascular evaluation before treatment with PERMAX® and periodically thereafter, and will specify a maximum recommended dose. Furthermore, PERMAX® is not recommended for patients with a history of fibrosis or inflammation of the heart, liver or kidney. If a patient develops cardiac valvular disease or a fibrotic condition while on PERMAX®, the drug should be discontinued. PERMAX® should not be discontinued abruptly as that could result in a worsening of the Parkinson symptoms, or the onset of confusion, or a symptom complex that includes fever, sweating and muscle rigidity. Clinicians are recommended to inform patients of the risk of valvulopathy with PERMAX®, and the Consumer Information will also be appropriately updated.

The safety of patients remains a top priority for Shire BioChem Inc. Information about adverse drug reactions is gathered by both Shire BioChem Inc. and Health Canada, via its Canadian Adverse Drug Reaction Monitoring Program (CADRMP)

Shire BioChem Inc.
275 Armand-Frappier Blvd
Laval, Que
H7V 4A7
Telephone: 1-800-268-2772
Fax: 450-978-7717

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

For other inquiries: please refer to contact information.

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

PERMAX®, is the registered trademark of Eli Lilly and Company. Shire BioChem Inc. acquired the Canadian distribution rights for PERMAX® in July 2003.

[Text of letter ends]

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime